These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38305755)

  • 1. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glofitamab: First Approval.
    Shirley M
    Drugs; 2023 Jul; 83(10):935-941. PubMed ID: 37285013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M
    N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of bispecific antibodies in relapsed and refractory DLBCL.
    Lewis KL; Cheah CY
    Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
    Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
    Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
    Bröske AE; Korfi K; Belousov A; Wilson S; Ooi CH; Bolen CR; Canamero M; Alcaide EG; James I; Piccione EC; Carlile DJ; Dimier N; Umaña P; Bacac M; Weisser M; Dickinson M
    Blood Adv; 2022 Feb; 6(3):1025-1037. PubMed ID: 34941996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting.
    Wang C; Liu Y
    J Hematol Oncol; 2023 Mar; 16(1):20. PubMed ID: 36895020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
    Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
    Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
    Cassanello G; Luna de Abia A; Falchi L
    Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance of radiotherapy with concomitant glofitamab in diffuse large B cell lymphoma: a case report.
    Loap P; Johnson N; Birsen R; Decroocq J; Kirova Y
    Strahlenther Onkol; 2024 Jul; ():. PubMed ID: 38955824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan.
    Hsu YT; Wu SJ; Kao HW; Hsiao SY; Liao CK; Chen TY; Wang MC
    Cancer; 2024 Jun; 130(11):1972-1981. PubMed ID: 38306242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
    Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
    Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
    Carlo-Stella C
    Br J Haematol; 2024 Jul; 205(1):17-19. PubMed ID: 38813657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.
    Rentsch V; Seipel K; Banz Y; Wiedemann G; Porret N; Bacher U; Pabst T
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data.
    Birtas Atesoglu E; Gulbas Z; Uzay A; Ozcan M; Ozkalemkas F; Dal MS; Kalyon H; Akay OM; Deveci B; Bekoz H; Sevindik OG; Toptas T; Yilmaz F; Koyun D; Alkis N; Alacacioglu I; Sonmez M; Yavasoglu I; Tombak A; Mehtap O; Kurnaz F; Yuce OK; Karakus V; Turgut M; Kurekci DD; Ayer M; Keklik M; Buyuktas D; Ozbalak M; Ferhanoglu B
    Hematol Oncol; 2023 Oct; 41(4):663-673. PubMed ID: 37211991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.